Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today that it has selected Cardinal Health, Inc., a leading healthcare services company, as its third party logistics provider for its OncAlert® Oral Cancer product line.
Effective immediately, Cardinal Health will oversee execution, monitoring and reporting of the company’s supply chain logistics in the United States and international markets. This includes day-to-day support for a wide range of functions, including inventory and order management, shipping, accounts receivable, billings and collections, as well as customer service, as it relates to order shipments.
Vigilant Biosciences’ OncAlert Oral Cancer product line includes the OncAlert Oral Cancer RAPID Test (“OncAlert RAPID Test”) and the OncAlert Oral Cancer LAB Test (“OncAlert LAB Test”). As previously announced, the OncAlert LAB Test was CE registered in November 2015, and Vigilant Biosciences expects to begin shipping the product during the second quarter of 2016. The OncAlert RAPID Test is currently undergoing the CE Mark registration process.
“Cardinal Health’s expertise in third party logistics, its global recognition, and presence in the Life Sciences space made them our top choice for our fulfillment needs,” said Matthew H.J. Kim, Founder, Chairman, and CEO of Vigilant Biosciences, Inc. “Our company is poised for rapid growth over the next 24 months, with the launch of our OncAlert Oral Cancer product line in international and domestic markets, and Cardinal Health is the right partner to help us support that growth while ensuring the best possible experience for our customers.”
“Vigilant Biosciences is an innovator in the early detection of cancer and Cardinal Health is excited to support their growth with our 3PL services. We look forward to a strong partnership,” said Jennifer Fillman, Vice President and General Manager of Specialty Services for Cardinal Health.
About the OncAlert Oral Cancer Product Line
Vigilant Biosciences’ initial products, the OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test are the first and only technologies that measure soluble CD44 and total protein levels – protein markers clinically shown to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. Both products use a simple, oral rinse collection and measurement procedure that is easy to administer and non-invasive for the patient. The accurate, cost-effective tests can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The OncAlert Oral Cancer product line is not yet available for sale in the U.S.
About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $103 billion health care services company that improves the cost-effectiveness of health care. Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers, clinical laboratories and physician offices focus on patient care while reducing costs, enhancing efficiency and improving quality. Cardinal Health is an essential link in the health care supply chain, providing pharmaceuticals and medical products and services to more than 100,000 locations each day and is also the industry-leading direct-to-home medical supplies distributor. The company is a leading manufacturer of medical and surgical products, including gloves, surgical apparel and fluid management products. In addition, the company operates the nation’s largest network of radiopharmacies that dispense products to aid in the early diagnosis and treatment of disease. Ranked #26 on the Fortune 500, Cardinal Health employs nearly 35,000 people worldwide. More information about the company may be found at www.cardinalhealth.com/pharma3pl and @CardinalHealth on Twitter.
About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. Vigilant’s OncAlert Oral Cancer product line includes rapid and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The OncAlert Oral Cancer product line is not yet available for sale in the U.S. For more information, visit www.vigilantbiosciences.com.